Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 5/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742780 | 0.86 | SLC6A12 (0.38) | SLC6A12SLC6A11SLC6A13AKR1C4AKR1C3 | |
| SCHEMBL20142223 | 0.80 | SLC6A12 (0.43) | SLC6A12SLC6A11SLC6A13AKR1C4AKR1C3 | |
| SCHEMBL13992044 | 0.78 | SLC6A12 (0.41) | SLC6A12SLC6A11SLC6A13AKR1C4AKR1C3 | |
| SCHEMBL10716749 | 0.78 | TSHR (0.34) | — | |
| SCHEMBL10716754 | 0.78 | TSHR (0.34) | — | |
| SCHEMBL6076661 | 0.77 | SLC6A12 (0.44) | SLC6A12SLC6A11SLC6A13AKR1C4AKR1C3 | |
| SCHEMBL9278180 | 0.75 | SLC6A12 (0.57) | SLC6A12SLC6A11SLC6A13AKR1C4AKR1C3 | |
| SCHEMBL12993394 | 0.74 | — | — | |
| SCHEMBL1861904 | 0.74 | — | — | |
| SCHEMBL25678378 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746401-B | Ionizable lipids for nucleic acid delivery | 精密纳米系统无限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3986866-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc (CA) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020252589-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | Precision Nanosystems Inc. (CA) | 2020-12-24 | — | — | WO | disclosed |
| US-20150335560-A1 | COSMETIC COMPOSITION | L'OREAL (FR) | 2015-11-26 | — | — | US | disclosed |
| US-20150335560-A1 | COSMETIC COMPOSITION | L'OREAL (FR) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335560-A1 | COSMETIC COMPOSITION | LIPA, LIPE, PLIN5 | SLC6A12 1553/4885SLC6A11 3634/4885SLC6A13 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.